Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Catalent : Launches New OptiDose® Design Solution to Help Create Differentiated Treatments that are Successful for Innovators, Patients and Health Care Professionals

07/26/2021 | 09:18am EDT

SOMERSET, N.J. - July 26, 2021 - Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the launch of its new OptiDose® Design Solution, at the Controlled Release Society (CRS) annual meeting, which is taking place virtually from July 25 - 29, 2021.

Catalent's OptiDose Design Solution, led by Catalent's scientific advisors, uses a design approach that combines data-driven scientific tools with Catalent's extensive development expertise. Integrating pharmaceutics, and dose form design target patient characteristics, OptiDose Design Solution will help craft the ideal dose form for all stakeholders and optimize the potential of a molecule.

'Taking patient needs and market realities into consideration earlier in the drug development process, along with critical CMC and DMPK parameters, is vital for creating a successful treatment for patients, innovators and health care professionals alike,' commented Julien Meissonnier, Chief Scientific Officer at Catalent. He continued, 'The OptiDose Design platform looks to evaluate all these considerations and provide options for final dose form decisions with an optimal combination of patient acceptance and adherence, differentiation versus any standard of care, manufacturability and cost.'

At the CRS meeting, Lisa Caralli, Director of Science and Technology at Catalent, will discuss the methodology of the OptiDose Design Solution, including how key product and patient factors are evaluated. Ms. Caralli's presentation, titled 'Strategies to Optimize the Dose Design Process to Create Better Treatments', will use case studies to demonstrate how the correct guidance, at the optimum time, can help drug developers create better treatments.

Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with pharmaceutical companies to identify appropriate development pathways for early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals and began her career at the Immune Response Corporation. Ms. Caralli holds a bachelor's degree in biochemistry from the University of California at Davis, California.

OptiDose Design Solution is available throughout Catalent's global oral dose network. For more information, please visit https://www.catalent.com/oral-dose/dose-form-design/optidose-design-solution.


Catalent Inc. published this content on 26 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2021 13:17:06 UTC.

© Publicnow 2021
All news about CATALENT, INC.
09/16CATALENT : Signs Commercial Supply Agreement with Phathom Pharmaceuticals
09/09Catalent to Seek Acquisitions
09/08CATALENT : Deutsche Bank Adjusts Catalent PT to $162 From $123, Maintains Hold R..
09/07CATALENT, INC. : to Present at the Morgan Stanley 19th Annual Global Healthcare ..
09/02CATALENT : Yumda - Catalent to Extend Leadership in Rapidly Growing Nutraceutica..
09/02VC DAILY : Laronde Fundraising Haul Reflects Search for Next Moderna
09/01Today on Wall Street: A new chapter
09/01ANALYST RECOMMENDATIONS : American Water, Broadcom, Enerplus, Pixelworks, Verint..
08/31CATALENT : JPMorgan Adjusts Catalent's Price Target to $155 From $140, Maintains..
08/31CATALENT : Jefferies Adjusts Catalent's Price Target to $152 From $140, Reiterat..
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Financials (USD)
Sales 2022 4 508 M - -
Net income 2022 487 M - -
Net Debt 2022 2 374 M - -
P/E ratio 2022 50,8x
Yield 2022 -
Capitalization 23 263 M 23 263 M -
EV / Sales 2022 5,69x
EV / Sales 2023 5,10x
Nbr of Employees 17 300
Free-Float 99,4%
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 12
Last Close Price 136,15 $
Average target price 153,90 $
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli President & Chief Operating Officer
Thomas P. Castellano Chief Financial Officer & Senior Vice President
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
CATALENT, INC.30.83%23 263
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556